Get started
Avadel Pharmaceuticals plcAvadel Pharmaceuticals plcAvadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

AVDL trade ideas

Technical Analysis of $AVDL Current Market Overview The stock NASDAQ:AVDL is exhibiting strong bullish momentum, with a promising risk-to-reward ratio that favors an upward movement. Based on recent price action and key technical indicators, the first target level is set at $8.96, representing a 15.9% profit potential from the current entry price. Risk Management and Stop-Loss Strategy To protect against downside risks, a stop-loss is placed at $7.44, limiting potential losses to 3.8%. A trailing stop strategy may also be employed to secure gains while allowing the stock to continue its upward trajectory. Profit/Loss Ratio & Risk-Reward Assessment The trade setup presents an excellent risk-to-reward ratio of 4.2:1, indicating that for every dollar risked, there is a potential return of 4.2 dollars. This makes the trade highly favorable from a risk management perspective. Conclusion Given the technical setup, NASDAQ:AVDL presents a strong buying opportunity with a well-defined exit strategy. Traders should monitor key support and resistance levels, as well as volume trends, to validate the trade's potential success.
NASDAQ:AVDL
by swingstocktraders
[AVDL] Small Caps land for a pharmaceutical positionThis asset has been in my watchlist for a while, with a lot of good entries on it for a long term bullish scenario. Here we can see a lot of confluence on this level for a potential long entry. We have multiples support from different timeframe (daily one and 4h one too), the fibonacci retracement level perfect bounce (needs to hold it now) and a liquidity trap. This asset can fall very quick so let's be flexible on it and cut the position when the price come back at us Great Trade !
NASDAQ:AVDLLong
by ArnoSG
AVDL Strong Conviction Swing LongHere is a spot I have been waiting for since the $16.0 rejection level (big absorption of the buyers on the top). Same mecanique as my EUR/USD swing position previously with a smooth spot at $10.0 psychological and technical level of interest. First breakdown of the level with then a new high as high as the previous one (little bit higher) for then a retest of the $10.0 with strong rejection pattern/candle, confirming my strong conviction for an entry (also a double bottom). My biggest optimistic target will be $25.0 with a 150% gain potentially. On the break of the $11.50 level noted on the chart, my conviction will keep growing as we are forming a new uptrend chart. Great Trade !
NASDAQ:AVDLLong
by ArnoSG
AVDL hedged options strategyDublin-headquartered biopharmaceutical company Avadel Pharmaceuticals currently has a buzzy formulation of sodium oxybate in a Phase 3 clinical trial for the treatment of narcolepsy, among other candidates. The current twice-nightly U.S. narcolepsy oxybate market is estimated at $1.8 billion -- up to half of those patients quit because they need to wake up in the middle of the night to take the second dose. AVDL's LUMRYZ, taken once before bedtime and offering much more ease of use, was recently granted tentative approval by the FDA. Speculatively, in an era where melatonin use and sleep studies are so common, specialized research in sleep disorders and cataplexy may also lead to other medical breakthroughs. Looking at the last wick on the weekly chart, the bulls seem to want to push the stock up. Will the uptrend continue? According to its profile on Yahoo Finance, it's a Strong Buy. Here's a hedged options trading strategy that makes up to 38% (33% annualized) on AVDL and also protects from a price drop of up to 44% as of 1/19/24. Buy 2 $7.50 call Sell 2 $10 call Sell 3 $5 put Exp 1/19/24 Capital required: $1450
NASDAQ:AVDLLong
by oliveinvest
AVDL pre-PDUFA run up entryAvadel Pharmaceuticals is a biotech company which is currently anticipating approval for FT218, a drug treating narcolepsy. Im not gonna go in depth on it cuz it really doesn’t matter for the swing I'm tryna do, but basically breakthrough therapies like FT218 are highly demanded by investors. Thus, when it breaks out of this multi-year consolidation zone (the PDUFA anticipation being the catalyst) it will likely carry up 20+%. Playing this based on the fib levels, 9.50 (18.9% up from current levels) would be the first target and 10.75 (34.5% up from current levels) would be the final target. Although it is possible for it to run up to 14.34, it is highly unlikely unless a squeeze happens (short float only 10%, which is low) or big news comes out. Make sure to sell before PDUFA date, though, since major selling after the FDA decision is common, whether or not the FDA approves or rejects FT218. I'm not a financial advisor and everything I have said thus far is all my opinion, not financial advice. Please trade only what you are willing to risk, as trading biotechs can be very risky.
NASDAQ:AVDLLong
by rhtrader123
$AVDL can fall in the next daysContextual immersion trading strategy idea. Avadel Pharmaceuticals operates as a specialty pharmaceutical company in the United States, France, and Ireland. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $5,23; stop-loss — $5,89. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:AVDLShort
by KozakHlib
Big Decisions with AVDL Next WeekFor the past year we can see that the market was not taking any price above 3.59. It mostly stayed between a range of 1.7 to 3.59. But recently the chart broke out on 9/19-9/23 and then started to fall back to its original range. the next couple weeks show promising strong movement. If it falls back into its yearly range it will stay there with 3.59 being its resistance. However if next week and can trend upwards, then I believe AVDL has finally found new support and we will see a cup and handle pattern. Depending on what happens next week with AVDL, whether it falls back into its yearly range, I will short or go long. This is definitely on my watchlist. Currently I am looking to short, since we can see that there has been no uptrend this past month and AVDL has recently fallen below 3.59 so the cup & handle pattern is not every evident. But I still need to see more price action AND NEW LOWS to make my decision next week!
NASDAQ:AVDLShort
by Closedeals
$AVDL STRONG WATCH ON FDA NEWS*******STRONG BREAKOUT COMING**** Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 15, 2019. “If approved, AV001 will be our fourth revenue producing Hospital Product,” said Greg Divis, interim Chief Executive Officer of Avadel. “We are pleased that the FDA has granted AV001 an accelerated 6-month Priority Review. Subsequent to our NDA submission, the FDA granted an NDA approval for a parenteral product with the same Active Pharmaceutical Ingredient (API) as AV001. We will continue to monitor the marketplace as we work with FDA on our application and prepare for a successful launch of AV001.” AVADEL PHARMACEUTICALS PLC ADR Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland
NASDAQ:AVDLLong
by DEXWireNews